197 related articles for article (PubMed ID: 22448028)
1. Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24.
Chang SY; Hudon-Miller SE; Yang SH; Jung HJ; Lee JM; Farber E; Subramanian T; Andres DA; Spielmann HP; Hrycyna CA; Young SG; Fong LG
J Lipid Res; 2012 Jun; 53(6):1176-82. PubMed ID: 22448028
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C; Hudon SE; Farber EA; Chang SY; Hrycyna CA; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13432-7. PubMed ID: 17652517
[TBL] [Abstract][Full Text] [Related]
3. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
4. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Coffinier C; Hudon SE; Lee R; Farber EA; Nobumori C; Miner JH; Andres DA; Spielmann HP; Hrycyna CA; Fong LG; Young SG
J Biol Chem; 2008 Apr; 283(15):9797-804. PubMed ID: 18230615
[TBL] [Abstract][Full Text] [Related]
5. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
6. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
Barrowman J; Hamblet C; Kane MS; Michaelis S
PLoS One; 2012; 7(2):e32120. PubMed ID: 22355414
[TBL] [Abstract][Full Text] [Related]
7. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
8. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.
Dominici S; Fiori V; Magnani M; Schena E; Capanni C; Camozzi D; D'Apice MR; Le Dour C; Auclair M; Caron M; Novelli G; Vigouroux C; Maraldi NM; Lattanzi G
Eur J Histochem; 2009; 53(1):43-52. PubMed ID: 19351612
[TBL] [Abstract][Full Text] [Related]
9. Drugs affecting prelamin A processing: effects on heterochromatin organization.
Mattioli E; Columbaro M; Capanni C; Santi S; Maraldi NM; D'Apice MR; Novelli G; Riccio M; Squarzoni S; Foisner R; Lattanzi G
Exp Cell Res; 2008 Feb; 314(3):453-62. PubMed ID: 18093584
[TBL] [Abstract][Full Text] [Related]
10. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.
Fong LG; Ng JK; Meta M; Coté N; Yang SH; Stewart CL; Sullivan T; Burghardt A; Majumdar S; Reue K; Bergo MO; Young SG
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18111-6. PubMed ID: 15608054
[TBL] [Abstract][Full Text] [Related]
11. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.
Wang Y; Shilagardi K; Hsu T; Odinammadu KO; Maruyama T; Wu W; Lin CS; Damoci CB; Spear ED; Shin JY; Hsu W; Michaelis S; Worman HJ
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35197292
[TBL] [Abstract][Full Text] [Related]
12. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect.
Bergo MO; Gavino B; Ross J; Schmidt WK; Hong C; Kendall LV; Mohr A; Meta M; Genant H; Jiang Y; Wisner ER; Van Bruggen N; Carano RA; Michaelis S; Griffey SM; Young SG
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13049-54. PubMed ID: 12235369
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
14. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
Davies BS; Barnes RH; Tu Y; Ren S; Andres DA; Spielmann HP; Lammerding J; Wang Y; Young SG; Fong LG
Hum Mol Genet; 2010 Jul; 19(13):2682-94. PubMed ID: 20421363
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis.
Candelario J; Borrego S; Reddy S; Comai L
Exp Cell Res; 2011 Feb; 317(3):319-29. PubMed ID: 20974128
[TBL] [Abstract][Full Text] [Related]
16. Deficiency in ZMPSTE24 and resulting farnesyl-prelamin A accumulation only modestly affect mouse adipose tissue stores.
Heizer PJ; Yang Y; Tu Y; Kim PH; Chen NY; Hu Y; Yoshinaga Y; de Jong PJ; Vergnes L; Morales JE; Li RL; Jackson N; Reue K; Young SG; Fong LG
J Lipid Res; 2020 Mar; 61(3):413-421. PubMed ID: 31941672
[TBL] [Abstract][Full Text] [Related]
17. Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.
Wood KM; Spear ED; Mossberg OW; Odinammadu KO; Xu W; Michaelis S
PLoS One; 2020; 15(12):e0239269. PubMed ID: 33315887
[TBL] [Abstract][Full Text] [Related]
18. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation.
Ben Yaou R; Navarro C; Quijano-Roy S; Bertrand AT; Massart C; De Sandre-Giovannoli A; Cadiñanos J; Mamchaoui K; Butler-Browne G; Estournet B; Richard P; Barois A; Lévy N; Bonne G
Eur J Hum Genet; 2011 Jun; 19(6):647-54. PubMed ID: 21267004
[TBL] [Abstract][Full Text] [Related]
19. LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
Afonso P; Auclair M; Boccara F; Vantyghem MC; Katlama C; Capeau J; Vigouroux C; Caron-Debarle M
Atherosclerosis; 2016 Feb; 245():200-11. PubMed ID: 26724531
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
